Showing results (1241-1250 of 1,512) with videos related to
Sort By:
Pageof 152
Current Medical Research and Opinion|October 5, 2019
Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysisByoung Chul Cho, Dong-Wan Kim, Keunchil Park, et al.BMC Cancer|May 29, 2008
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic markerBhumsuk Keam, Seock-Ah Im, Sae-Won Han, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, et al.Journal of the American Heart Association|June 3, 2022
Association Between Systolic Blood Pressure Variability and Major Adverse Cardiovascular Events in Korean Patients With Chronic Kidney Disease: Findings From KNOW-CKDCheol Ho Park, Hyung Woo Kim, Young Su Joo, et al.Pancreas|January 15, 2008
Is pancreatic core biopsy sufficient to diagnose autoimmune chronic pancreatitis?Sung-Jo Bang, Myung-Hwan Kim, Do Ha Kim, et al.Cancer Research and Treatment|September 2, 2017
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid TumorsTae Min Kim, Keun-Wook Lee, Do-Youn Oh, et al.BMC Cancer|April 14, 2007
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapyKyung-Hun Lee, Seock-Ah Im, Do-Youn Oh, et al.International Journal of Antimicrobial Agents|March 14, 2008
In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteriaHosung Sohn, Kil-Soo Lee, Young-Kwan Ko, et al.European Radiology|August 27, 2020
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapyJong Keon Jang, Jae Ho Byun, Ji Hun Kang, et al.Blood|July 25, 2006
Phospholipase D2 acts as an essential adaptor protein in the activation of Syk in antigen-stimulated mast cellsJun Ho Lee, Young Mi Kim, Nam Wook Kim, et al.Pageof 152